BioCardia Q2 net loss narrows on lower R&D costs

BioCardia

12/08/2026 21:17

Overview
Cellular therapeutics developer's Q2 net loss narrowed yr/yr on lower R&D expenses
Company ended Q2 with $4.1 mln in cash after raising $4.9 mln during the quarter
Q2 R&D expenses fell as CardiAMP HF trial closed out, offset by new trial and regulatory work

Outlook
BioCardia plans CardiAMP Cell Therapy regulatory submission to Japan PMDA in Q4 2026
Company continues CardiAMP Cell Therapy development in the USA with ongoing FDA engagement
BioCardia pursuing strategic partnerships and licensing for Helix/Heart3D and allogeneic MSC platform

Result Drivers
R&D EXPENSES - Lower research and development expenses due to closeout of CardiAMP HF trial, partially offset by early enrollment in CardiAMP HF II trial and regulatory activities

Company press release: ID:nGNX3JtJzR

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$1.61 mln
 
Q2 Loss Per Basic Share
 
$0.13
 
Q2 Operating Income
 
-$1.62 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for BioCardia Inc is $15.50, about 1,562.9% above its August 11 closing price of $0.93

Reuters Recommended Reads
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise
Aug 12 - TScan Therapeutics Q2 net loss narrows on lower R&D costs
Aug 11 - Theriva Biologics Q2 net loss narrows on lower R&D costs, expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)